AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04391634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pressure-controlled
Description: pressure-controlled assist-control mechanical ventilation
Study NCT04189705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT-SR
Description: Rebamipide 150mg
Study NCT04189705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCT-SR
Description: Rebamipide 150mg
Study NCT02715349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
Study NCT04189705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucosta Tab.
Description: Rebamipide 100mg
Study NCT04189705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucosta Tab.
Description: Rebamipide 100mg
Study NCT04950829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional brackets
Description: These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
Study NCT04950829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Description: These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
Study NCT04950829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-Ligating Brackets with flapless corticotomy
Description: These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only.
Study NCT02316860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive tilt test
Description: Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
Study NCT01619839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181
Study NCT02093000 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
Study NCT00944398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc fortified food
Description: Daily consumption
Study NCT00944398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: Liquid supplement containing zinc sulfate
Study NCT01619839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
Study NCT00088530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone
Description: Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
Study NCT00088530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
Description: Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
Study NCT02539641 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Gastric emptying scintigraphy
Description: Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
Study NCT00944398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Liquid placebo supplement
Study NCT00944398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Description: Liquid placebo supplement
Study NCT00944398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified food
Description: Non-fortified complementary food.
Study NCT00944398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fortified food
Description: Non-fortified complementary food.
Study NCT02539641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of gut hormones
Description: Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
Study NCT00878163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00878163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00878163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00878163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT01176032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg film coated tablets
Study NCT01176032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 100 mg tablets
Study NCT01176032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.
Study NCT01176032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.
Study NCT01176032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
Study NCT01176032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: I.V. infusion of placebo for 8 hr
Study NCT01806103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial Stewardship Bundle
Description: Guidelines, Education, Audit and Feedback
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
Study NCT02728869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat Stable Rotavirus (HSRV) Vaccine
Description: It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
Study NCT02728869 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Heatstable Rotavirus vaccine
Description: It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
Study NCT02728869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®
Description: It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7\[5\]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A\[8\]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
Study NCT00704379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an inactive substance
Study NCT00704379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
Study NCT01638234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: melatonin 3 mg tab 1 tab po hs for 4 weeks
Study NCT01638234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch pill
Study NCT02479048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal 1
Description: High fat meal (HF) with ½ avocado (\~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
Study NCT02479048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal 2
Description: High fat meal (HF) with 1 avocado (\~136g) matched for energy but not macronutrient content or type.
Study NCT02479048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Meal (CM)
Description: High carbohydrate, high saturated fat control meal (CM) without avocado.
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
Study NCT01380223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
Study NCT02845817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative research
Description: Semi-structured interviews
Study NCT03787186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690 film-coated tablets
Description: a single oral dose of GLPG1690
Study NCT03787186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1690 solution for infusion
Description: a 15-minute IV infusion \[14C\]-GLPG1690
Study NCT03787186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1690 capsules
Description: single oral dose of \[14C\]-GLPG1690
Study NCT06249685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral hearing devices
Description: Three week trial while wearing bilateral hearing devices.
Study NCT02461381 — intervention group
Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study for estimation of diagnostic performance.
Study NCT04610047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Oral capsule
Study NCT04610047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT01379417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplementation
Description: 1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
Study NCT01379417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplementation
Description: 1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
Study NCT03669367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
Study NCT03669367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxycloroquina
Description: oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
Study NCT00596986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30mg up to 120mg per day.
Study NCT00596986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Analysis System of Psychotherapy
Description: Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
Study NCT03882892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg tablets
Study NCT03882892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovastatin
Description: Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
Study NCT03882892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atovastatin
Description: Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
Study NCT03882892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to ezetimibe
Study NCT01665196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
Study NCT01175863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)
Description: minimal lumen area on Intravascular ultrasound
Study NCT01175863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure wire(Radi Medical Systems)
Description: Fractional flow reserve measured by pressure wire
Study NCT02525471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase.
Study NCT02907424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 months of treatment
Description: standard 2 months of treatment
Study NCT02907424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 months of treatment
Description: standard 2 months of treatment
Study NCT00519519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: intravenous 80mg bolus followed by 8mg / hr for 3 days
Study NCT04261998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service-learning program
Description: Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
Study NCT04376216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 60 mg with dose tapering over 2 months
Study NCT04125043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Direct ophthalmoscope
Description: Red reflex test
Study NCT04325893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
Study NCT04325893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
Study NCT02447965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
Study NCT02447965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
Study NCT02707068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Of LIfe Tool for IBD (QOLITI)
Description: The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
Study NCT02913482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally.
Study NCT03061071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightBalance Sleep Position Trainer (SPT)
Description: Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
Study NCT03806621 — intervention group
Intervention type: PROCEDURE
Intervention: Rotational Atherectomy
Description: Patients with severe calcified lesions will receive rotational atherectomy during index PCI
Study NCT02186613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support
Description: Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
Study NCT03061071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Adjusting Positive Airway Pressure (APAP)
Description: Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
Study NCT03143530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectoralis block
Description: Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).